HPV-16 E7 expression up-regulates phospholipase D activity and promotes rapamycin resistance in a pRB-dependent manner
Carregando...
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Autores
RABACHINI, Tatiana
BOCCARDO, Enrique
ANDRADE, Rubiana
PEREZ, Katia Regina
NONOGAKI, Suely
CUCCOVIA, Iolanda Midea
Citação
BMC CANCER, v.18, article ID 485, 8p, 2018
Resumo
Background: Human Papillomavirus (HPV) infection is the main risk factor for the development and progression of cervical cancer. HPV-16 E6 and E7 expression is essential for induction and maintenance of the transformed phenotype. These oncoproteins interfere with the function of several intracellular proteins, including those controlling the PI3K/AKT/mTOR pathway in which Phospolipase D (PLD) and Phosphatidic acid (PA) play a critical role. Methods: PLD activity was measured in primary human keratinocytes transduced with retroviruses expressing HPV-16 E6, E7 or E7 mutants. The cytostatic effect of rapamycin, a well-known mTOR inhibitor with potential clinical applications, was evaluated in monolayer and organotypic cultures. Results: HPV-16 E7 expression in primary human keratinocytes leads to an increase in PLD expression and activity. Moreover, this activation is dependent on the ability of HPV-16 E7 to induce retinoblastoma protein (pRb) degradation. We also show that cells expressing HPV-16 E7 or silenced for pRb acquire resistance to the antiproliferative effect of rapamycin. Conclusion: This is the first indication that HPV oncoproteins can affect PLD activity. Since PA can interfere with the ability of rapamycin to bind mTOR, the use of combined strategies to target mTOR and PLD activity might be considered to treat HPV-related malignancies.
Palavras-chave
HPV, E7, PLD, Phospholipase, Rapamycin, Phosphatidic acid, PA, mTOR, pRb
Referências
- Basile JR, 2001, J BIOL CHEM, V276, P22522, DOI 10.1074/jbc.M010505200
- BLANTON RA, 1991, AM J PATHOL, V138, P673
- Boccardo E, 2004, VIROLOGY, V328, P233, DOI 10.1016/j.virol.2004.07.026
- Boccardo E, 2010, CARCINOGENESIS, V31, P521, DOI 10.1093/carcin/bgp333
- Boyer SN, 1996, CANCER RES, V56, P4620
- Buchkovich NJ, 2008, NAT REV MICROBIOL, V6, P265, DOI 10.1038/nrmicro1855
- Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565
- Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688
- Coppock JD, 2016, ONCOTARGET, V7, P24228, DOI 10.18632/oncotarget.8286
- D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497
- Demers GW, 1996, J VIROL, V70, P6862
- Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015
- Foster DA, 2003, MOL CANCER RES, V1, P789
- Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016
- Gillison ML, 2008, J NATL CANCER I, V100, P407, DOI 10.1093/jnci/djn025
- HAWLEYNELSON P, 1989, EMBO J, V8, P3905
- Hebner CM, 2006, REV MED VIROL, V16, P83, DOI 10.1002/rmv.488
- Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159
- Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001
- Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091
- Jung EM, 1999, CARCINOGENESIS, V20, P569, DOI 10.1093/carcin/20.4.569
- Kurmasheva RT, 2006, BRIT J CANCER, V95, P955, DOI 10.1038/sj.bjc.6603353
- Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001
- McLaughlin-Drubin ME, 2009, VIROLOGY, V384, P335, DOI 10.1016/j.virol.2008.10.006
- Menges CW, 2006, CANCER RES, V66, P5555, DOI 10.1158/0008-5472.CAN-06-0499
- Paavonen J, 2007, INT J INFECT DIS, V11, pS3, DOI 10.1016/S1201-9712(07)60015-0
- Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571
- SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8
- Stelzer MK, 2010, CANCER PREV RES, V3, P1542, DOI 10.1158/1940-6207.CAPR-10-0228
- Sun YT, 2008, CELL CYCLE, V7, P3118, DOI 10.4161/cc.7.20.6881
- Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08
- Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
- Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316
- Yoon MS, 2015, MOL CELL, V58, P549, DOI 10.1016/j.molcel.2015.03.028
- Yoon MS, 2011, J CELL BIOL, V195, P435, DOI 10.1083/jcb.201107033
- Zhang LF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0361-x